Celecoxib

Celecoxib belongs to the class of selective cyclooxygenase-2 inhibitors, often called coxibs, a subgroup of the nonsteroidal anti-inflammatory drugs ^[1][2]. Its molecular formula is C17H14F3N3O2S, corresponding to a molar mass of about 381 grams per mole, and its structure contains a sulfonamide group; that feature matters clinically because people with an allergy to sulfonamide drugs may react to it as well ^[1]. It is taken by mouth, usually in capsule form ^[1].

The drug was discovered by chemists at the Searle division of Monsanto, in work led by John Talley, and it was patented in 1993 ^[1]. The United States Food and Drug Administration approved celecoxib at the end of 1998, and Pfizer went on to market it under the brand name Celebrex ^[1]. It was among the first selective COX-2 inhibitors to reach wide clinical use, and after its patent lapsed around 2014 it became broadly available as a low-cost generic; it remains one of the more commonly prescribed medicines in the United States ^[1].

Celecoxib is approved to treat osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile rheumatoid arthritis, and it is also used for acute pain and for painful menstruation ^[1]. Randomized trials and systematic reviews have found NSAIDs, including selective COX-2 inhibitors, effective for menstrual pain, though the evidence has not clearly singled out any one agent as best ^[4]. The drug additionally has a niche role in reducing the number of colorectal polyps in people with familial adenomatous polyposis, although its ability to prevent cancer itself is not established ^[1].

A central theme in celecoxib's history is cardiovascular safety ^[1][3]. The selective COX-2 inhibitors as a group came under scrutiny after some were linked to raised risks of heart attack and stroke, and a pooled analysis reported that coxibs increased major cardiovascular events relative to placebo ^[1]. A large randomized trial published in 2016, comparing moderate-dose celecoxib with ibuprofen and naproxen in patients at increased cardiovascular risk, found celecoxib to be no worse than those older drugs for cardiovascular outcomes while causing fewer gastrointestinal and kidney problems ^[3]. On the strength of such data a United States advisory panel later revisited and softened earlier warnings about the drug ^[1].

Celecoxib is a prescription medicine available in most countries as capsules, both branded and generic ^[1]. It is not recommended in the later part of pregnancy or during breastfeeding, and it is avoided in people with a known sulfonamide allergy ^[1]. As with all NSAIDs, prescribers weigh its benefits against the risk of heart, stomach, and kidney effects and generally use the lowest effective dose for the shortest necessary time ^[1][3].

Celecoxib is prescription only and carries boxed warnings shared by NSAIDs. It can raise the risk of heart attack and stroke, especially at higher doses or with long term use, and it can worsen high blood pressure, cause fluid retention, and strain the kidneys. Although it is easier on the stomach than older NSAIDs, serious gastrointestinal bleeding and ulcers are still possible. Because it is a sulfonamide, people with a sulfa allergy should be cautious. It should be avoided in late pregnancy and used carefully in those with heart, kidney, or liver disease.

Celecoxib is a substrate of CYP2C9 and can be subject to pharmacokinetic interactions with CYP2C9 inhibitors. Fluconazole, a moderate inhibitor of CYP2C9, increases celecoxib plasma area-under-the-curve by 2.2 to 2.6-fold depending on CYP2C9 genotype, with the effect most pronounced in patients with the *1/*1 genotype ^[6]. This is a pharmacokinetic interaction where the inhibitor reduces celecoxib clearance and prolongs its half-life.

Celecoxib combined with warfarin shows a mild but non-statistically significant increase in bleeding complications; the mechanism is thought to be pharmacodynamic (additive effects on platelet function and the gastrointestinal tract), though the clinical risk appears lower than with non-selective NSAIDs ^[7]. Other CYP2C9 inhibitors (ketoconazole, voriconazole, amiodarone) have not been specifically tested with celecoxib but would be expected to produce similar increases in exposure. Most OTC medications and many antihistamines have not been studied with celecoxib; these pairings are poorly characterized.

Checking a whole stack? Run it through interactions + stacks.

Celecoxib emerged from research at G. D. Searle and Company in the 1990s, following the discovery that cyclooxygenase exists as two isoforms and the hypothesis that selectively blocking the inflammation-associated COX-2 form could relieve pain while sparing the COX-1 that protects the stomach lining. It became the first selective COX-2 inhibitor, or coxib, approved by the United States Food and Drug Administration in 1998, reaching the market under the brand name Celebrex and rapidly becoming one of the best-selling drugs of its era.

Its commercial life was shaped by the wider coxib story, including the 2004 withdrawal of the related drug rofecoxib over cardiovascular concerns, which intensified scrutiny of the entire class. Large safety studies followed, and the drug survived where some competitors did not; it is now widely available as a generic. Celecoxib remains approved for osteoarthritis, rheumatoid arthritis, and other painful inflammatory conditions.

Celecoxib is regarded as the enduring success of the COX-2 inhibitor class, valued for delivering meaningful relief of arthritic pain and inflammation with a notably lower rate of stomach ulcers and gastrointestinal bleeding than older nonselective NSAIDs. Because it does not appreciably block COX-1 in platelets, it lacks the blood-thinning effect of aspirin, which can be an advantage in patients at risk of bleeding.

Its cardiovascular safety was the central question of its history, and later large comparative trials helped reassure prescribers that, at commonly used doses, its cardiovascular risk was not clearly worse than that of traditional NSAIDs. Rheumatologists and pain specialists continue to view it as a useful option, particularly for patients vulnerable to gastric injury. Honest discussion still emphasizes that, like all NSAIDs, it carries cardiovascular, renal, and other risks that guide careful use.